Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective

doi:10.4251/wjgo.v16.i11.4489

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1158)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-5) series.

Item

Count

PDF

HTML

659

Figures (1-7)

Tables (1-5)

Sum=848

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=162

Publishing Process of This Article

Item

Count

Browse

Download

Sum=110

Nov 15, 2024 (publication date) through Jan 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Scientometrics

World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4489-4505
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4489

Table 1 The top 10 most popular countries/regions conducting research on olaparib and pancreatic cancer

Rank	Country	Counts	TLCS	TGCS
1	United States	83	320	4760
2	China	48	16	366
3	United Kingdom	31	241	3748
4	France	19	140	1537
5	Italy	19	124	1040
6	Germany	16	192	2254
7	Spain	12	186	2352
8	Australia	9	75	1746
9	Belgium	9	130	1391
10	Israel	9	179	2120

TLCS: Total local citation score; TGCS: Total global citation score.

Citation: Feng X, Chai YH, Jiang KX, Jiang WB, Chen WC, Pan Y. Bibliometric analysis of olaparib and pancreatic cancer from 2009 to 2022: A global perspective. World J Gastrointest Oncol 2024; 16(11): 4489-4505
URL: https://www.wjgnet.com/1948-5204/full/v16/i11/4489.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i11.4489